Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis

NCT05366855 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.

NCT NCT05366855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Lead sponsor
Vanda Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
April 21, 2022
Completion date
July 12, 2024
Enrollment
42 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

generalized pustular psoriasis